 ScreeningInformed Consent: Sixteen subjects will be recruited for the clinical protocol and replacements will be recruited if necessary for 16 subjects to complete the protocol. Screening and a separate informed consent process will take place as in the pharmacokinetic study previously described with the following exceptions: Subjects will be genotyped to determine if they are poor metabolizers of CYP2D6 substrates. Subjects will also be asked about adverse events according to a Treatment Emergent Symptoms Scale TESS Zhang et al., 2001 to determine if any symptoms are present prior to administration of the MT supplement. Subjects will be asked about their diets including alcohol use and the use of herbal medicationsdietary supplements. If a potential subject has been consuming any herbal or dietary supplements a two week period of abstinence from supplement use will be necessary before beginning the next study phase. 